Patents by Inventor Gunars Valkirs

Gunars Valkirs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid encoding anti-IL13 human antibodies
    Patent number: 9650438
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: May 16, 2017
    Assignee: Novartis AG
    Inventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Nucleic Acid Encoding Anti-IL13 Human Antibodies
    Publication number: 20170101467
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: February 24, 2015
    Publication date: April 13, 2017
    Applicant: Novartis AG
    Inventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Methods of Using Anti-IL13 Human Antibodies
    Publication number: 20150259411
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: February 24, 2015
    Publication date: September 17, 2015
    Applicant: Novartis AG
    Inventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Methods of using anti-IL13 human antibodies
    Patent number: 8992916
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: March 31, 2015
    Assignee: Novartis AG
    Inventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
    Patent number: 8969018
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: March 3, 2015
    Assignee: Alere San Diego, Inc.
    Inventors: Gunars Valkirs, Paul H. McPherson
  • METHODS AND COMPOSITIONS FOR MONITORING AND RISK PREDICTION IN CARDIORENAL SYNDROME
    Publication number: 20140349868
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
    Type: Application
    Filed: March 4, 2014
    Publication date: November 27, 2014
    Applicant: ALERE SAN DIEGO, INC.
    Inventors: GUNARS VALKIRS, PAUL H. MCPHERSON
  • Anti-IL 13 Human Antibodies
    Publication number: 20140023660
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: October 2, 2013
    Publication date: January 23, 2014
    Applicant: NOVARTIS AG
    Inventors: Emma Michelle CAMPBELL, Sofia PARVEEN, Joe BUECHLER, Gunars VALKIRS
  • Method of using anti-IL-13 antibodies
    Patent number: 8580260
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: November 12, 2013
    Assignee: Novartis AG
    Inventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Methods and compositions for diagnosis and prognosis of renal artery stenosis
    Patent number: 8524462
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects in the context of renal artery stenosis (RAS). In particular, the invention relates to using assays that detect NGAL, their use to diagnose RAS in subjects suffering from hypertension, and their use in prognosis, particularly of mortality and worsening renal function.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: September 3, 2013
    Assignee: Alere San Diego, Inc.
    Inventors: Gunars Valkirs, Paul H. McPherson
  • Methods and Compositions for Monitoring and Risk Prediction in Cardiorenal Syndrome
    Publication number: 20130122527
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
    Type: Application
    Filed: July 3, 2012
    Publication date: May 16, 2013
    Inventors: Gunars Valkirs, Paul H. McPherson
  • Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
    Patent number: 8283128
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: October 9, 2012
    Assignee: Alere San Diego, Inc.
    Inventors: Gunars Valkirs, Paul H. McPherson
  • Methods and Compositions for Monitoring and Risk Prediction in Cardiorenal Syndrome
    Publication number: 20110281280
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
    Type: Application
    Filed: June 2, 2011
    Publication date: November 17, 2011
    Applicant: Alere San Diego, Inc.
    Inventors: Gunars Valkirs, Paul H. McPherson
  • Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
    Patent number: 7985560
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: July 26, 2011
    Assignee: Alere San Diego, Inc.
    Inventors: Gunars Valkirs, Paul H. McPherson
  • Methods and Compositions for Monitoring and Risk Prediction in Cardiorenal Syndrome
    Publication number: 20110104726
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
    Type: Application
    Filed: October 21, 2010
    Publication date: May 5, 2011
    Applicant: Alere International
    Inventors: Gunars Valkirs, Paul H. McPherson
  • ANTI-IL 13 HUMAN ANTIBODIES
    Publication number: 20110091458
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: December 22, 2010
    Publication date: April 21, 2011
    Inventors: Emma CAMPBELL, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Anti-IL13 human antibodies
    Patent number: 7910708
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: March 22, 2011
    Assignee: Novartis AG
    Inventors: Emma Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
    Patent number: 7842472
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: November 30, 2010
    Assignee: Alere International
    Inventors: Gunars Valkirs, Paul H. McPherson
  • Methods and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis
    Publication number: 20100086944
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects in the context of renal artery stenosis (RAS). In particular, the invention relates to using assays that detect NGAL, their use to diagnose RAS in subjects suffering from hypertension, and their use in prognosis, particularly of mortality and worsening renal function.
    Type: Application
    Filed: November 14, 2007
    Publication date: April 8, 2010
    Inventors: Gunars Valkirs, Paul H. McPherson
  • Anti-Il13 Human Antibodies
    Publication number: 20080267959
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Application
    Filed: October 19, 2006
    Publication date: October 30, 2008
    Inventors: Emma Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Methods And Compositions For Monitoring And Risk Prediction In Cardiorenal Syndrome
    Publication number: 20080254485
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
    Type: Application
    Filed: November 14, 2007
    Publication date: October 16, 2008
    Applicant: Biosite Incorporated
    Inventors: Gunars Valkirs, Paul H. McPherson